Presenters
Dean, College of Medicine, UERMMMC
Norbert Lingling D. Uy, M.D., MSPH, FPCP, FPCC, FPSE, FACC, FACP
Course Details
Hypertension is a common risk factor for the development of atrial fibrillation, which may lead to various complications including ischemic stroke. In this webinar, Dr. Norbert Lingling-Uy (UERMMC, Quezon City) described the role of BP control via RAS blockade on the primary prevention of AF. Professor Chee Kok Han (University Malaya, Malaysia) then shared real-world data on the efficacy and safety of non-Vitamin K oral anticoagulants in the secondary prevention of AF.
Estimated Time of Completion: 21 mins. 47 sec.
CPD Points: 0.5 Point
PRC Program No: PROG-2022-46154
RAS Blockade in the Management of Hypertension in AF Recurrence Prevention Course Outline
- Prevalence of Hypertension
- PRESYON 4
- Hypertension and AF
- 2020 ESC Guidelines: Primary prevention of AF
- High-risk Patients: Advantage of RAAS inhibitors
- ACEI / ARBs in AF prevention among HPN patients
- ARBs and CCBs in preventing AF recurrence in patients with hypertension and AF : A meta-analysis
- LAAT in ACEI / ARB treated AF patients
- Telmisartan: ARB developed by Boehringer Ingelheim
- Pharmacological Profile of Telmisartan
- The Through/Peak Ratio
- Telmisartan’s Long Duration of Effect
- ONTARGET: Telmisartan is as effective as Ramipril in Preventing CV Events at increased CV risk
- Telmisartan and AF Recurrences in Patients with Hypertension: A Systematic Review and Meta-analysis
- Summary
PC-PH-104170 / September 2023